We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
You may need to tell DVLA if you have cancer - if you do, download the correct form to let them know
You may need to tell DVLA if you have lung cancer - download the correct form if you need to let them know
Quarterly updates to the emergency presentations of cancer data by Public Health England.
This national report provides insights into the care experienced by cancer patients across England who were treated as day cases or inpatients during the first three months of 2010.
Government bringing together experts in the field to drive forward progress in tackling cancer in children and young people.
Collection of cancer survival statistics produced by the UK Health Security Agency (UKHSA).
Lead and co-ordinate PHE’s cancer-related work to support the Independent Cancer Taskforce recommendations to prevent and beat cancer.
Information on the waiting times of patients with suspected cancer and those subsequently diagnosed with cancer.
Following MHRA approval of a clinical trial, early breast cancer patients on endocrine-based therapy can benefit from a study with camizestrant.
Information on the waiting times of patients with suspected cancer and those subsequently diagnosed with cancer
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (11 March 2024) approved the medicine quizartinib (Vanflyta) to be used alongside chemotherapy as first line treatment for adults who have acute myeloid leukaemia (AML).
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.